{
    "data": [
        {
            "id": "4566716",
            "type": "article",
            "attributes": {
                "publishOn": "2022-12-28T10:18:09-05:00",
                "isLockedPro": false,
                "commentCount": 10,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1396614976/image_1396614976.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Johnson & Johnson: Aspects To Consider After Acquiring Abiomed",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "105351",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "428105",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1135",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4566716-johnson-and-johnson-aspects-to-consider-after-acquiring-abiomed"
            }
        },
        {
            "id": "4566529",
            "type": "article",
            "attributes": {
                "publishOn": "2022-12-27T09:59:03-05:00",
                "isLockedPro": false,
                "commentCount": 9,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1353290150/image_1353290150.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Johnson & Johnson: Healthcare For The Win",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "53262",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "428019",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1135",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4566529-jnj-healthcare-for-the-win"
            }
        },
        {
            "id": "4562720",
            "type": "article",
            "attributes": {
                "publishOn": "2022-12-06T14:47:10-05:00",
                "isLockedPro": false,
                "commentCount": 3,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1396614976/image_1396614976.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Johnson & Johnson: Reducing Corporate Risk And Increasing Growth",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "106324",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "424216",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1135",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4562720-johnson-and-johnson-reducing-corporate-risk-and-increasing-growth"
            }
        },
        {
            "id": "4562461",
            "type": "article",
            "attributes": {
                "publishOn": "2022-12-05T16:56:29-05:00",
                "isLockedPro": false,
                "commentCount": 10,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1325253083/image_1325253083.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Johnson & Johnson: Alzheimer's Disease Pipeline Could Dominate",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "75375",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "424025",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1135",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4562461-johnson-and-johnson-alzheimers-disease-pipeline-could-dominate"
            }
        },
        {
            "id": "4562131",
            "type": "article",
            "attributes": {
                "publishOn": "2022-12-03T07:30:00-05:00",
                "isLockedPro": false,
                "commentCount": 141,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/476541270/image_476541270.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Johnson & Johnson: Time To Buy Before The Split",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "103599",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "423727",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1135",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4562131-johnson-and-johnson-buy-before-split"
            }
        },
        {
            "id": "4562152",
            "type": "article",
            "attributes": {
                "publishOn": "2022-12-03T05:56:07-05:00",
                "isLockedPro": false,
                "commentCount": 12,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1352916474/image_1352916474.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Johnson & Johnson: Boring, But Worth Having In A Portfolio",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "95326",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "423754",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1135",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4562152-johnson-and-johnson-boring-worth-in-portfolio"
            }
        },
        {
            "id": "4554195",
            "type": "article",
            "attributes": {
                "publishOn": "2022-11-07T03:53:42-05:00",
                "isLockedPro": false,
                "commentCount": 37,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1163587098/image_1163587098.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Johnson & Johnson: Steady Growth Play",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "25120",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "418669",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1135",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4554195-johnson-and-johnson-steady-growth-play"
            }
        },
        {
            "id": "4551983",
            "type": "article",
            "attributes": {
                "publishOn": "2022-11-02T11:46:58-04:00",
                "isLockedPro": false,
                "commentCount": 9,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1210336572/image_1210336572.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Johnson & Johnson Goes Back Into Cardiology With A Big Splash",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "24361",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "418006",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1135",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4551983-johnson-and-johnson-jnj-back-into-cardiology-with-big-splash"
            }
        },
        {
            "id": "4550014",
            "type": "article",
            "attributes": {
                "publishOn": "2022-10-27T15:50:57-04:00",
                "isLockedPro": false,
                "commentCount": 30,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1163587098/image_1163587098.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Johnson & Johnson: Attractive Opportunity During Market Turmoil",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "103640",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "416978",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1135",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4550014-johnson-and-johnson-attractive-opportunity-during-market-turmoil"
            }
        },
        {
            "id": "4548106",
            "type": "article",
            "attributes": {
                "publishOn": "2022-10-21T11:10:13-04:00",
                "isLockedPro": false,
                "commentCount": 4,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1170407888/image_1170407888.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Johnson & Johnson: Currency, Kenvue, And Cash Allocation Focus Of Q3 2022 Earnings",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "104985",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "415778",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1135",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4548106-johnson-and-johnson-q3-2022-earnings-currency-kenvue-cash-allocation-focus"
            }
        },
        {
            "id": "4547398",
            "type": "article",
            "attributes": {
                "publishOn": "2022-10-20T07:15:00-04:00",
                "isLockedPro": false,
                "commentCount": 25,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1291620275/image_1291620275.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "3 Reasons To Love Johnson & Johnson, But Buy These 2 Better Dividend Aristocrat Bargains",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "101900",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "415146",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1135",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4547398-3-reasons-love-johnson-and-johnson-buy-2-better-dividend-aristocrat-bargains"
            }
        },
        {
            "id": "4547518",
            "type": "article",
            "attributes": {
                "publishOn": "2022-10-19T12:54:52-04:00",
                "isLockedPro": false,
                "commentCount": 4,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/501707914/image_501707914.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Terumo And Johnson & Johnson Pair Trade: One With Headwinds, One With Tailwinds",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "105817",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "415249",
                            "type": "sentiment"
                        },
                        {
                            "id": "415250",
                            "type": "sentiment"
                        },
                        {
                            "id": "415251",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1135",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4547518-terumo-and-johnson-and-johnson-pair-trade-one-with-headwinds-one-with-tailwinds"
            }
        },
        {
            "id": "4546533",
            "type": "article",
            "attributes": {
                "publishOn": "2022-10-14T04:16:52-04:00",
                "isLockedPro": false,
                "commentCount": 7,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1225119943/image_1225119943.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Johnson & Johnson: Shorts Represent Nearly Half Of The Total Trading Volume (Technical Analysis)",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "32611",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "414341",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1135",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4546533-johnson-and-johnson-shorts-nearly-half-trading-volume-technical-analysis"
            }
        },
        {
            "id": "4546448",
            "type": "article",
            "attributes": {
                "publishOn": "2022-10-13T14:58:17-04:00",
                "isLockedPro": false,
                "commentCount": 9,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1352916474/image_1352916474.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Johnson & Johnson Looks Undervalued Heading Into Third Quarter Earnings",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "24361",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "414294",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1135",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4546448-johnson-and-johnson-q3-earnings-preview-stock-undervalued"
            }
        },
        {
            "id": "4545083",
            "type": "article",
            "attributes": {
                "publishOn": "2022-10-06T13:55:24-04:00",
                "isLockedPro": false,
                "commentCount": 23,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1134001812/image_1134001812.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Talc Scandal Clouds Investment Attractiveness Of Johnson & Johnson's Pharmaceutical Business",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "106297",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "412951",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1135",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4545083-talc-scandal-clouds-investment-attractiveness-of-johnson-and-johnsons-pharmaceutical-business"
            }
        },
        {
            "id": "4544983",
            "type": "article",
            "attributes": {
                "publishOn": "2022-10-06T08:45:00-04:00",
                "isLockedPro": false,
                "commentCount": 28,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1396614976/image_1396614976.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Johnson & Johnson: Stability In A Rather Unstable Market",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "103599",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "412786",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1135",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4544983-johnson-and-johnson-jnj-stability-in-unstable-market"
            }
        },
        {
            "id": "4542308",
            "type": "article",
            "attributes": {
                "publishOn": "2022-09-21T13:24:57-04:00",
                "isLockedPro": false,
                "commentCount": 5,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1163587098/image_1163587098.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Johnson & Johnson: A Defensive Recession Play For A Rocky Economy",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "106277",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "410177",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1135",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4542308-johnson-and-johnson-defensive-recession-play-rocky-economy"
            }
        },
        {
            "id": "4542160",
            "type": "article",
            "attributes": {
                "publishOn": "2022-09-20T18:37:27-04:00",
                "isLockedPro": false,
                "commentCount": 16,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1163587098/image_1163587098.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Outlooks Continue To Favor Johnson & Johnson",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "20102",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "410187",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1135",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4542160-outlooks-continue-to-favor-johnson-and-johnson"
            }
        },
        {
            "id": "4536479",
            "type": "article",
            "attributes": {
                "publishOn": "2022-08-23T15:09:22-04:00",
                "isLockedPro": false,
                "commentCount": 18,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1003107348/image_1003107348.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Johnson & Johnson And Arrowhead Pharmaceuticals Could Have Big News Coming",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "101571",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "389052",
                            "type": "sentiment"
                        },
                        {
                            "id": "389053",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1135",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4536479-johnson-and-johnson-and-arrowhead-pharmaceuticals-could-have-big-news-coming"
            }
        },
        {
            "id": "4536025",
            "type": "article",
            "attributes": {
                "publishOn": "2022-08-21T11:06:25-04:00",
                "isLockedPro": false,
                "commentCount": 19,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1221879711/image_1221879711.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Gilead Vs. Johnson & Johnson: Who's The Better Dividend Stock?",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "106207",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "388753",
                            "type": "sentiment"
                        },
                        {
                            "id": "388754",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1135",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4536025-gilead-vs-johnson-and-johnson-whos-better-dividend-stock"
            }
        },
        {
            "id": "4532505",
            "type": "article",
            "attributes": {
                "publishOn": "2022-08-10T11:52:29-04:00",
                "isLockedPro": false,
                "commentCount": 27,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1163587098/image_1163587098.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Dividend Aristocrat Johnson & Johnson: One Of The Best Ideas Out There",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "24491",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "386965",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1135",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4532505-dividend-aristocrat-johnson-and-johnson-one-of-the-best-ideas-out-there"
            }
        },
        {
            "id": "4529126",
            "type": "article",
            "attributes": {
                "publishOn": "2022-08-04T08:00:00-04:00",
                "isLockedPro": false,
                "commentCount": 27,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/171286371/image_171286371.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Johnson & Johnson And AbbVie: 2 Great Dividend Aristocrats For What's Coming Next",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "101900",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "385839",
                            "type": "sentiment"
                        },
                        {
                            "id": "385840",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1135",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4529126-johnson-and-johnson-abbvie-great-dividend-aristocrats-whats-coming-next"
            }
        },
        {
            "id": "4525898",
            "type": "article",
            "attributes": {
                "publishOn": "2022-07-26T13:07:40-04:00",
                "isLockedPro": false,
                "commentCount": 4,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1352916404/image_1352916404.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Johnson & Johnson: Everything An Investor Needs To Know Before Buying",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "104985",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "384569",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1135",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4525898-johnson-and-johnson-everything-an-investor-needs-to-know-before-buying"
            }
        },
        {
            "id": "4524632",
            "type": "article",
            "attributes": {
                "publishOn": "2022-07-21T01:30:00-04:00",
                "isLockedPro": false,
                "commentCount": 2,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1180491673/image_1180491673.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Mayar Capital - Johnson & Johnson: A Commendable 20% To 25% ROIC",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "105080",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": []
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1135",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4524632-johnson-and-johnson-a-commendable-20-percent-to-25-percent-roic"
            }
        },
        {
            "id": "4524495",
            "type": "article",
            "attributes": {
                "publishOn": "2022-07-20T13:10:04-04:00",
                "isLockedPro": false,
                "commentCount": 8,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1180491673/image_1180491673.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Johnson & Johnson: Satisfactory Results In A Complex Macroeconomic Environment",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "106075",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "383531",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1135",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4524495-johnson-and-johnson-satisfactory-results-in-a-complex-macroeconomic-environment"
            }
        },
        {
            "id": "4523655",
            "type": "article",
            "attributes": {
                "publishOn": "2022-07-15T16:16:57-04:00",
                "isLockedPro": false,
                "commentCount": 16,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1352916404/image_1352916404.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Is Johnson & Johnson Stock A Buy Before Upcoming Earnings? Yes, When You Want A Low-Risk Play",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "68315",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "382899",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1135",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4523655-is-johnson-and-johnson-stock-buy-before-earnings"
            }
        },
        {
            "id": "4523511",
            "type": "article",
            "attributes": {
                "publishOn": "2022-07-15T07:21:17-04:00",
                "isLockedPro": false,
                "commentCount": 10,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1288732014/image_1288732014.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Johnson & Johnson: Like A Mutual Fund Of Health Care Products",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "49201",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "382729",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1135",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4523511-johnson-and-johnson-mutual-fund-health-care-products"
            }
        },
        {
            "id": "4523002",
            "type": "article",
            "attributes": {
                "publishOn": "2022-07-12T22:28:07-04:00",
                "isLockedPro": false,
                "commentCount": 4,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1309235591/image_1309235591.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Johnson & Johnson: What To Know Before Upcoming Earnings",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "106380",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "382361",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1135",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4523002-johnson-and-johnson-what-to-know-upcoming-earnings"
            }
        },
        {
            "id": "4518719",
            "type": "article",
            "attributes": {
                "publishOn": "2022-06-16T05:35:19-04:00",
                "isLockedPro": false,
                "commentCount": 11,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1220627489/image_1220627489.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Johnson & Johnson Or Novo Nordisk: Which Is The Best Big Pharma Near Cap-Gainer",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "23468",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "378494",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1135",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4518719-johnson-and-johnson-novo-nordisk-near-cap-gainer"
            }
        },
        {
            "id": "4518510",
            "type": "article",
            "attributes": {
                "publishOn": "2022-06-15T08:24:43-04:00",
                "isLockedPro": false,
                "commentCount": 8,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1225119943/image_1225119943.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Johnson & Johnson Is A Safe Haven In The Current Turmoil",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "102214",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "378351",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1135",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4518510-johnson-and-johnson-safe-haven-current-turmoil"
            }
        },
        {
            "id": "4518474",
            "type": "article",
            "attributes": {
                "publishOn": "2022-06-15T04:34:15-04:00",
                "isLockedPro": false,
                "commentCount": 8,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1352916404/image_1352916404.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Johnson & Johnson: Why Add Here If It Could Underperform",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "106173",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "378468",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1135",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4518474-johnson-johnson-stock-why-add-here-if-it-could-underperform"
            }
        },
        {
            "id": "4518387",
            "type": "article",
            "attributes": {
                "publishOn": "2022-06-14T16:15:37-04:00",
                "isLockedPro": false,
                "commentCount": 9,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1316093183/image_1316093183.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Johnson & Johnson: Safety In Healthcare",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "25319",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "378281",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1135",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4518387-johnson-and-johnson-safety-in-healthcare"
            }
        },
        {
            "id": "4511550",
            "type": "article",
            "attributes": {
                "publishOn": "2022-05-14T07:38:11-04:00",
                "isLockedPro": false,
                "commentCount": 11,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1170407888/image_1170407888.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Johnson & Johnson: Priced About Right",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "90335",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "373911",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1135",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4511550-johnson-and-johnson-stock-fully-valued"
            }
        },
        {
            "id": "4511227",
            "type": "article",
            "attributes": {
                "publishOn": "2022-05-13T11:33:50-04:00",
                "isLockedPro": false,
                "commentCount": 6,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1309235591/image_1309235591.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Focus On Fundamentals In Stormy Markets: Johnson & Johnson",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "24157",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "373777",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1135",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4511227-focus-on-fundamentals-in-stormy-markets-johnson-and-johnson"
            }
        },
        {
            "id": "4510496",
            "type": "article",
            "attributes": {
                "publishOn": "2022-05-12T03:18:30-04:00",
                "isLockedPro": false,
                "commentCount": 7,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1180491673/image_1180491673.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Johnson & Johnson: A Cash Cow At A Fair-To-Premium Valuation",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "106178",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "373496",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1135",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4510496-johnson-and-johnson-cash-cow-fair-to-premium-valuation"
            }
        },
        {
            "id": "4501753",
            "type": "article",
            "attributes": {
                "publishOn": "2022-04-16T10:55:16-04:00",
                "isLockedPro": false,
                "commentCount": 9,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Stocks To Watch: Twitter Twists + Earnings For Netflix, J&J And Tesla",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "68015",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": []
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1135",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4501753-stocks-to-watch-twitter-twists-plus-earnings-for-netflix-j-and-j-and-tesla"
            }
        },
        {
            "id": "4501005",
            "type": "article",
            "attributes": {
                "publishOn": "2022-04-12T12:41:27-04:00",
                "isLockedPro": false,
                "commentCount": 11,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1305098938/image_1305098938.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Johnson & Johnson: This Low-Risk, High-Growth, Highly Credible Stock Is A Strong Buy",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "106556",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "369300",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1135",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4501005-johnson-and-johnson-this-low-risk-high-growth-and-highly-credible-stock-is-a-strong-buy"
            }
        },
        {
            "id": "4500439",
            "type": "article",
            "attributes": {
                "publishOn": "2022-04-08T09:48:07-04:00",
                "isLockedPro": false,
                "commentCount": 42,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1352916474/image_1352916474.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Johnson & Johnson Stock Has Broken Out And Is Going Higher",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "39011",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "368896",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1135",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4500439-johnson-and-johnson-broken-out-going-higher"
            }
        },
        {
            "id": "4500403",
            "type": "article",
            "attributes": {
                "publishOn": "2022-04-08T05:50:08-04:00",
                "isLockedPro": false,
                "commentCount": 39,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1352916404/image_1352916404.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Johnson & Johnson Vs. AbbVie: Why We Hold AbbVie",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "106207",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "368857",
                            "type": "sentiment"
                        },
                        {
                            "id": "368858",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1135",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4500403-johnson-and-johnson-vs-abbvie-hold"
            }
        },
        {
            "id": "4493404",
            "type": "article",
            "attributes": {
                "publishOn": "2022-03-07T11:44:42-05:00",
                "isLockedPro": false,
                "commentCount": 22,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1316093183/image_1316093183.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Johnson & Johnson: Still A Bit Too Expensive",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "102404",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "364507",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1135",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4493404-johnson-and-johnson-still-a-bit-too-expensive"
            }
        },
        {
            "id": "4493378",
            "type": "article",
            "attributes": {
                "publishOn": "2022-03-07T10:04:40-05:00",
                "isLockedPro": false,
                "commentCount": 0,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1055668286/image_1055668286.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Johnson & Johnson: Your 101 Guide To Litigation Protection - Bankruptcy",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "106485",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "364464",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1135",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4493378-johnson-and-johnson-guide-to-litigation-protection"
            }
        },
        {
            "id": "4485672",
            "type": "article",
            "attributes": {
                "publishOn": "2022-02-09T20:17:09-05:00",
                "isLockedPro": false,
                "commentCount": 15,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/155443388/image_155443388.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Give Your Portfolio A Blue-Chip Dividend Booster Shot With Johnson & Johnson",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "106404",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "360745",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1135",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4485672-give-portfolio-blue-chip-dividend-booster-shot-johnson-and-johnson"
            }
        },
        {
            "id": "4484159",
            "type": "article",
            "attributes": {
                "publishOn": "2022-02-04T08:25:00-05:00",
                "isLockedPro": false,
                "commentCount": 6,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1288732014/image_1288732014.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Is Johnson & Johnson Stock A Buy Or Sell After Recent Earnings?",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "39591",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "359339",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1135",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4484159-johnson-and-johnson-stock-buy-sell-recent-earnings"
            }
        },
        {
            "id": "4481340",
            "type": "article",
            "attributes": {
                "publishOn": "2022-01-25T01:44:15-05:00",
                "isLockedPro": false,
                "commentCount": 2,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1163587098/image_1163587098.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Johnson & Johnson: The Right Prescription For A Turbulent Market",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "69575",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "358388",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1135",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4481340-johnson-and-johnson-the-right-prescription-for-a-turbulent-market"
            }
        },
        {
            "id": "4481229",
            "type": "article",
            "attributes": {
                "publishOn": "2022-01-24T12:38:46-05:00",
                "isLockedPro": false,
                "commentCount": 10,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1163587098/image_1163587098.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Johnson & Johnson Stock: Spinning Off Its Litigations And Bankruptcy",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "106173",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "358427",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1135",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4481229-johnson-and-johnson-stock-spinning-off-litigations-and-bankruptcy"
            }
        },
        {
            "id": "4481150",
            "type": "article",
            "attributes": {
                "publishOn": "2022-01-24T07:52:32-05:00",
                "isLockedPro": false,
                "commentCount": 4,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1225119943/image_1225119943.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Johnson & Johnson Is The Low Beta Stock Your Portfolio Needs",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "80836",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "358366",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1135",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4481150-johnson-and-johnson-jnj-low-beta-stock-buy"
            }
        },
        {
            "id": "4481148",
            "type": "article",
            "attributes": {
                "publishOn": "2022-01-24T07:30:11-05:00",
                "isLockedPro": false,
                "commentCount": 9,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1163587098/image_1163587098.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Johnson & Johnson: It's Not A Matter Of If But When To Add This Stock",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "24206",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "358329",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1135",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4481148-johnson-and-johnson-add-jnj-stock"
            }
        },
        {
            "id": "4480992",
            "type": "article",
            "attributes": {
                "publishOn": "2022-01-22T09:57:59-05:00",
                "isLockedPro": false,
                "commentCount": 13,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Stocks To Watch: FOMC Meeting, Earnings Rush And Testing Times In Crypto",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "68015",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": []
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1135",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4480992-stocks-to-watch-fomc-meeting-earnings-rush-and-testing-times-in-crypto"
            }
        }
    ]
}